Roche continues to restructure diabetes unit

Roche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.

Read More

Lilly chases Novo in insulin race

Eli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.

Read More